These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2119246)

  • 1. Cyclophosphamide and ifosfamide: role of uroprotective agents.
    Williams SD; Munshi N; Einhorn LH; Loehrer PJ
    Cancer Invest; 1990; 8(2):269. PubMed ID: 2119246
    [No Abstract]   [Full Text] [Related]  

  • 2. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
    Andriole GL; Sandlund JT; Miser JS; Arasi V; Linehan M; Magrath IT
    J Clin Oncol; 1987 May; 5(5):799-803. PubMed ID: 3106585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical overview of mesna.
    Burkert H
    Cancer Treat Rev; 1983 Sep; 10 Suppl A():175-81. PubMed ID: 6414692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of N-acetylcysteine and mesna as uroprotectors with ifosfamide combination chemotherapy in refractory germ cell tumors.
    Munshi NC; Loehrer PJ; Williams SD; Langefeld C; Sledge G; Nichols CR; Roth BJ; Neuman A; Walsh WB; Einhorn LH
    Invest New Drugs; 1992 Aug; 10(3):159-63. PubMed ID: 1428725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical evaluation of Mitexan in the prevention of urinary tract complications during treatment with Holoxan].
    Czownicki Z; Utracka-Hutka B
    Nowotwory; 1981; 30(4):377-83. PubMed ID: 6792599
    [No Abstract]   [Full Text] [Related]  

  • 6. Ifosfamide/mesna and hematuria.
    Pratt CB; Goren MP
    Cancer Treat Rep; 1987 Nov; 71(11):1124-5. PubMed ID: 3119210
    [No Abstract]   [Full Text] [Related]  

  • 7. [Effects of mesna (2-mercaptoethane sodium sulfonate) in children with malignant disease receiving oxazaphosphorine chemotherapy].
    Iwasaku-Fujimoto M; Fujiwara F; Todo S; Morioka Y; Imashuku S
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):403-6. PubMed ID: 2106836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma.
    Jürgens H; Exner U; Kühl J; Ritter J; Treuner J; Weinel P; Winkler K; Göbel U
    Cancer Chemother Pharmacol; 1989; 24 Suppl 1():S40-4. PubMed ID: 2503258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ifosfamide, mesna, and encephalopathy.
    Lancet; 1985 Jun; 1(8442):1398-9. PubMed ID: 2861351
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of mesna in preventing further cyclophosphamide-induced hemorrhagic cystitis.
    Luce JK; Simons JA
    Med Pediatr Oncol; 1988; 16(6):372-4. PubMed ID: 3143903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [High-dose ifosfamide therapy: systemic use of a mucolytic agent for the reduction of urotoxicity].
    Marti C; Steiner R; Viollier AF
    Schweiz Med Wochenschr; 1979 Dec; 109(47):1885-7. PubMed ID: 119317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prevention of urinary tract toxicity of oxazaphosphorines by a "uroprotector". Report on a field study (author's transl)].
    Burkert H; Schnitker J; Fichtner E
    MMW Munch Med Wochenschr; 1979 Jun; 121(22):760-2. PubMed ID: 112422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irreversible encephalopathy with ifosfamide/mesna.
    Salloum E; Flamant F; Ghosn M; Taleb N; Akatchereian C
    J Clin Oncol; 1987 Aug; 5(8):1303-4. PubMed ID: 3114437
    [No Abstract]   [Full Text] [Related]  

  • 14. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma.
    Antman KH; Ryan L; Elias A; Sherman D; Grier HE
    J Clin Oncol; 1989 Jan; 7(1):126-31. PubMed ID: 2491883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination chemotherapy with adriamycin, ifosfamide and mesna in extensive-stage non-small cell bronchogenic carcinoma.
    Matthiessen W; Stempinski E; Göbel D; Thalmann U
    Cancer Treat Rev; 1983 Sep; 10 Suppl A():121-3. PubMed ID: 6414688
    [No Abstract]   [Full Text] [Related]  

  • 16. [Uroprotection with mesna in the chemotherapy of malignant tumors with oxazaphosphorines. Biometric evaluation of a sequential clinical study].
    Schnitker J
    Arzneimittelforschung; 1982; 32(10):1334-8. PubMed ID: 6817761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Encephalopathy associated with ifosphamide/mesna therapy.
    Meanwell CA; Blake AE; Latief TN; Blackledge G; Mould JJ; Blake DR; Shaw IC; Honigsberger L; Spooner D; Williams AC
    Lancet; 1985 Feb; 1(8425):406-7. PubMed ID: 2857462
    [No Abstract]   [Full Text] [Related]  

  • 18. The development of mesna for the inhibition of urotoxic side effects of cyclophosphamide, ifosfamide, and other oxazaphosphorine cytostatics.
    Brock N
    Recent Results Cancer Res; 1980; 74():270-8. PubMed ID: 6777836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ifosfamide/mesna encephalopathy.
    McCallum AK
    Lancet; 1987 Apr; 1(8539):987. PubMed ID: 2882385
    [No Abstract]   [Full Text] [Related]  

  • 20. Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-induced Hemorrhagic Cystitis.
    Matz EL; Hsieh MH
    Urology; 2017 Feb; 100():16-19. PubMed ID: 27566144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.